Stem Cell Tourism Near and Far

Patient advocacy groups have been strong supporters of stem cell and regenerative medicine research. But, after waiting more than a decade for scientists to complete clinical trials, many patients are now approaching clinics around the world that offer experimental stem cell-based interventions. Why did patients who were once strong supporters of stem cell research become stem cell tourists? And how can scientists, clinicians and regulators work to bring stem cell patients back to the U.S. and into the clinical trial process?

This panel discussion combines perspectives of a physician scientist, policy scholar, bioethicist and regulator to explore the risks surrounding stem cell tourism. Panelists will examine the FDA’s efforts to combat the issue within the U.S. and why the clinical trial process is the gold standard for understanding the impact of therapeutic interventions. The dialogue will highlight options for better cooperation and collaboration with the FDA to expedite proven therapies.

Speaker Joyce L. Frey-Vasconcells, Ph.D.


Thu, Sep. 22, 2016
7:30 a.m. - 9:30 a.m. US/Central


Doré Commons
6100 Main St.
Houston, TX 77005
United States

James A. Baker III Hall, Rice University

6100 Main St.
Houston, Texas 77005